Abstract

Theranostic radionuclides that emit Auger electrons (AE) can generate highly localised DNA damage and the accompanying gamma ray emission can be used for single-photon emission computed tomography (SPECT) imaging. Mismatched DNA base pairs (mismatches) are DNA lesions that are abundant in cells deficient in MMR (mismatch mediated repair) proteins. This form of genetic instability is prevalent in the MMR-deficient subset of colorectal cancers and is a potential target for AE radiotherapeutics. Herein we report the synthesis of a mismatch DNA binding bis-ruthenium(ii) dipyridophenazine (dppz) complex that can be radiolabelled with the Auger electron emitting radionuclide indium-111 (111In). Greater stabilisation accompanied by enhanced MLCT (metal to ligand charge-transfer) luminescence of both the bis-Ru(dppz) chelator and non-radioactive indium-loaded complex was observed in the presence of a TT mismatch-containing duplex compared to matched DNA. The radioactive construct [111In]In-bisRu(dppz) ([111In][In-2]4+) targets cell nuclei and is radiotoxic towards MMR-deficient human colorectal cancer cells showing substantially less detrimental effects in a paired cell line with restored MMR function. Additional cell line studies revealed that [111In][In-2]4+ is preferentially radiotoxic towards MMR-deficient colorectal cancer cells accompanied by increased DNA damage due to 111In decay. The biodistribution of [111In][In-2]4+ in live mice was demonstrated using SPECT. These results illustrate how a Ru(ii) polypyridyl complex can incorporate mismatch DNA binding and radiometal chelation in a single molecule, generating a DNA-targeting AE radiopharmaceutical that displays selective radiotoxicity towards MMR-deficient cancer cells and is compatible with whole organism SPECT imaging.

Highlights

  • The aim of targeted radionuclide therapy (TRT) is to employ a carrier molecule conjugated to a suitable radioisotope to deliver a radiotoxic dose of ionising radiation (IR) speci cally to cancer cells while sparing healthy tissue.1,2 Clinical TRT radiopharmaceuticals incorporating long-range b-emitting8936 | Chem

  • We report the synthesis of a mismatch DNA binding bis-ruthenium(II) dipyridophenazine complex that can be radiolabelled with the Auger electron emitting radionuclide indium-111 (111In)

  • Greater stabilisation accompanied by enhanced metal to ligand charge-transfer (MLCT) luminescence of both the bisRu(dppz) chelator and non-radioactive indium-loaded complex was observed in the presence of a TT mismatch-containing duplex compared to matched DNA

Read more

Summary

Introduction

The aim of targeted radionuclide therapy (TRT) is to employ a carrier molecule conjugated to a suitable radioisotope to deliver a radiotoxic dose of ionising radiation (IR) speci cally to cancer cells while sparing healthy tissue.1,2 Clinical TRT radiopharmaceuticals incorporating long-range b-emitting8936 | Chem.

Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.